Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives
Conclusion CYP2B6 slow metabolizer genotype worsens the pharmacokinetic interaction of efavirenz with hormonal contraceptives administered by vaginal ring. Efavirenz dose reduction in CYP2B6 slow metabolizers may reduce, but will likely not eliminate, this interaction. (Source: Pharmacogenetics and Genomics)
Source: Pharmacogenetics and Genomics - March 7, 2020 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research

Surface roughness of different contraceptive vaginal rings: evaluation by scanning electron microscope (SEM).
Conclusion: The different composition of the vaginal rings' EVA membrane is not associated with different surface roughness. Ornibel is equivalent to NuvaRing in terms of surface roughness, despite the different composition of the membrane polymers. PMID: 31922428 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - January 10, 2020 Category: Reproduction Medicine Authors: Grandi G, Timò A, Sammarini M, Del Savio MC, Facchinetti F Tags: Eur J Contracept Reprod Health Care Source Type: research

Annovera - A New Contraceptive Vaginal Ring
Date: December 16, 2019 Issue #:  1587Summary: Annovera (TherapeuticsMD), a contraceptive vaginal ring that releases segesterone acetate, a synthetic progestin, and ethinyl estradiol, was approved by the FDA in 2018 and is now available. It is the first product to contain segesterone and the second vaginal ring to become available in the US;NuvaRing, which delivers etonogestrel and ethinyl estradiol, was the first. UnlikeNuvaRing, which requires use of a new ring each month, theAnnovera ring can be used for an entire year, but it must be removed for one week each month. (Source: The Medical Letter)
Source: The Medical Letter - December 9, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Annovera Contraceptives Estrogens etonogestrel IUD Nexplanon NuvaRing ombitasvir paritaprevir Progestins Ritonavir segesterone Technivie Viekira Pak Source Type: research

In vitro evaluation of microbial adhesion to a contraceptive vaginal ring with a new polymer composition.
CONCLUSION: The study demonstrates that the adherence of C. albicans, as well as that of L. acidophilus when co-cultured with C. albicans, is lower with the Ornibel vaginal ring compared with NuvaRing. These in vitro findings warrant future human trials using molecular techniques to assess the vaginal microbiota composition and to establish whether Ornibel can support vaginal health. PMID: 30977415 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - April 12, 2019 Category: Reproduction Medicine Authors: Sailer M, Colli E, Regidor PA Tags: Eur J Contracept Reprod Health Care Source Type: research

Application for the etonogestrel/ethinyl estradiol ring (after) — Potential for emergency contraception
Objectives: We aimed to describe the emergency contraceptive (EC) potential of the 11.7-mg etonogestrel/2.7-mg ethinyl estradiol contraceptive vaginal ring when placed at different time points in the follicular phase of the menstrual cycle. (Source: Contraception)
Source: Contraception - September 13, 2018 Category: OBGYN Authors: D Crabtree Sokol, M Natavio, B Nguyen, A Nelson, N Bender Source Type: research

Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17 β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing.
CONCLUSIONS: Contraceptive rings releasing 300 µg E2 and 75-125 µg/day of ENG or 500-900 µg/day of NOMAC provided adequate ovulation inhibition and cycle control and are generally well-tolerated. While non-inferiority to NuvaRing® was not met, among the investigational rings, the ENG-E2 125/300 ring provided the best cycle control. PMID: 30203681 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - September 11, 2018 Category: Reproduction Medicine Authors: Duijkers I, Klipping C, Heger-Mahn D, Fayad GN, Frenkl TL, Cruz SM, Korver T Tags: Eur J Contracept Reprod Health Care Source Type: research

Poster 441: Out With the Old, in with the Nuvaring ®. Pudendal Neuralgia: A Novel Complication of the Nuvaring®: Case Report
Roberta Lui: I Have No Relevant Financial Relationships To Disclose (Source: PM and R)
Source: PM and R - September 1, 2017 Category: Rehabilitation Authors: Roberta Lui, Anna M. Lasak Source Type: research

The effects of the etonogestrel 0.12mg/ethinyl estradiol 0.015mg vaginal ring (NuvaRing ®) on inflammatory biomarkers
Certain types of hormonal contraception have been associated with alterations of the inflammatory balance which is of concern due to known association of proinflammatory activation with risk of HIV. We investigated how the use of NuvaRing ® alters biomarkers of inflammation in the vaginal compartment. (Source: Fertility and Sterility)
Source: Fertility and Sterility - September 1, 2017 Category: Reproduction Medicine Authors: T. Kimble, A. Thurman, R. Fichorova, D. Archer Tags: Poster session Source Type: research

Establishment of a Molding Procedure to Facilitate Formulation Development for Co-extrudates.
Abstract Co-extrusion offers a number of advantages over conventional manufacturing techniques. However, the setup of a co-extrusion line is cost- and time-intense and formulation development is challenging. This work introduces a novel procedure to test the applicability of a co-extruded reservoir-type system at an early product development stage. We propose vacuum compression molding (VCM), a fast procedure that requires only small material amounts, for the manufacturing of cylindrical reservoir-type system. To this end, the commercially available co-extruded product NuvaRing(®) and variations thereof were u...
Source: AAPS PharmSciTech - May 1, 2017 Category: Drugs & Pharmacology Authors: Eder S, Beretta M, Witschnigg A, Koutsamanis I, Eggenreich K, Khinast JG, Koscher G, Paudel A, Nickisch K, Friedrich M, Froehlich E, Roblegg E Tags: AAPS PharmSciTech Source Type: research

Stroke and Etonogestrel/Ethinyl Estradiol Ring (NuvaRing): Clinical, Radiological, and Prognostic Features
A recent study found that NuvaRing (a vaginal contraceptive ring containing 15  µg ethinyl estradiol and 120 µg etonogestrel) has 2.5 times increased relative risk of thrombotic stroke compared to nonuse. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - December 30, 2016 Category: Neurology Authors: Prad Selvan, Pirouz Piran, Clotilde Balucani, Brian Tark, Zachary Adler, Steven R. Levine Source Type: research

Comparison of combined hormonal vaginal ring and low dose combined oral hormonal pill for the treatment of idiopathic chronic pelvic pain: a randomised trial
Conclusion: Present study demonstrates for first time that both vaginal and oral hormonal therapy are effective in treatment of idiopathic chronic pelvic pain and vaginal ring may be a better choice with higher satisfaction rate and fewer side effects. (Source: European Journal of Obstetrics and Gynecology and Reproductive Biology)
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - November 8, 2016 Category: OBGYN Source Type: research

Comparison of combined hormonal vaginal ring and low dose combined oral hormonal pill for the treatment of idiopathic chronic pelvic pain: a randomised trial
Objective: To compare the efficacy and acceptability of combined hormonal vaginal ring with combined oral hormonal pill in women with idiopathic chronic pelvic pain. Study design: Randomised prospective interventional trial conducted in 60 women with idiopathic chronic pelvic pain. Women were randomised into two groups of 30 each. In each group, treatment was given for 84  days using either combined vaginal ring or combined oral hormonal pill. Hormonal vaginal ring releases 15mcg of ethinyl estradiol and 120mcg of the etonogestrel per day while the hormonal pill contained 30mcg of ethinyl estradiol and 150mcg of lev...
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - November 8, 2016 Category: OBGYN Authors: Khushboo Priya, Shalini Rajaram, Neerja Goel Source Type: research

Hormonal contraceptives for contraception in overweight or obese women.
We examined reference lists of pertinent articles to identify other studies. For the initial review, we wrote to investigators to find additional published or unpublished studies. SELECTION CRITERIA: All study designs were eligible. The study could have examined any type of hormonal contraceptive. Reports had to contain information on the specific contraceptive methods used. The primary outcome was pregnancy. Overweight or obese women must have been identified by an analysis cutoff for weight or BMI (kg/m(2)). DATA COLLECTION AND ANALYSIS: Two authors independently extracted the data. One entered the data into Re...
Source: Cochrane Database of Systematic Reviews - August 18, 2016 Category: Journals (General) Authors: Lopez LM, Bernholc A, Chen M, Grey TW, Otterness C, Westhoff C, Edelman A, Helmerhorst FM Tags: Cochrane Database Syst Rev Source Type: research

Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
CONCLUSIONS: Once-monthly NuvaRing is efficacious and safe for use in Chinese women. PMID: 27339759 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - June 24, 2016 Category: Reproduction Medicine Authors: Fan GS, Ren M, Di W, Su P, Chang Q, Wu S, Qin Y, Korver T, Marintcheva-Petrova M, Yacik C, McCrary Sisk C, Wang G Tags: Eur J Contracept Reprod Health Care Source Type: research

Safety and efficacy of the NuvaRing ® Applicator in healthy females: A multicenter, open-label, randomized, 2-period crossover study
We assessed performance and safety of the NuvaRing ® Applicator. (Source: Contraception)
Source: Contraception - May 17, 2016 Category: OBGYN Authors: Robert Feldman, Tara L. Frenkl, Carol Yacik, Yinna Wang, Michelle C. Fox Source Type: research

Effect of Hormonal Contraception on the Function of Plasmacytoid Dendritic Cells and Distribution of Immune Cell Populations in the Female Reproductive Tract
Conclusions: The presented evidence suggests that the use of some types of hormonal contraception is associated with reduced functional capacity of circulating pDCs and altered immune environment in the female reproductive tract. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - March 12, 2015 Category: Infectious Diseases Tags: Basic and Translational Science Source Type: research

The Case Files: Unusual Headache
By Al-Hashimi, Siddhartha DO; Leavens, John MD A 23-year-old woman with a history of migraine headaches presented to the emergency department for a different-than-usual headache. She had a six-day history of intermittent headaches. The onset was at rest, and there was no history of trauma.   The headache was located behind her left eye, and it radiated into the posterior portion of her head. She characterized it as being 8/10 in intensity. Bright lights were reported as an exacerbating factor. The headache was associated with nausea and multiple episodes of emesis. She had 10 episodes of vomiting the evening prior to ...
Source: The Case Files - June 5, 2014 Category: Emergency Medicine Tags: Blog Posts Source Type: research

Stroke and Etonogestrel/Ethinyl Estradiol Ring (NuvaRing): Clinical, Radiological, and Prognostic Features. (P2.012)
Conclusions: In this largest case series of NuvaRing associated stroke to date, approximately half of the strokes are venous and half are arterial. Stroke typically occurred within the first year of use, and as soon as 2 weeks after NuvaRing initiation.Disclosure: Dr. Piran has nothing to disclose. Dr. Balucani has nothing to disclose. Dr. Tark has nothing to disclose. Dr. Adler has nothing to disclose. Dr. Levine has received personal compensation in an editorial capacity for MedLink. Dr. Levine has received royalty payments as editor of a book. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Piran, P., Balucani, C., Tark, B., Adler, Z., Levine, S. Tags: Cerebrovascular Disease and Interventional Neurology I Source Type: research

Cerebral venous sinus thrombosis in the setting of combined vaginal contraception
We present a case of a 27-year-old women admitted to the hospital with migraine and left upper extremity weakness. Subsequent imaging with computed tomography and magnetic resonance angiography/venography demonstrated an acute-appearing central venous sinus thrombosis. Her only risk factor for venous thromboembolism (VTE) was the use of etonogestrel/ethinyl estradiol vaginal contraceptive ring (NuvaRing). The contraceptive ring was removed and the patient was treated according to the current guidelines. She achieved full neurologic recovery at 6 months’ follow-up. Here, we describe this unusual case and review the ri...
Source: Blood Coagulation and Fibrinolysis - February 3, 2014 Category: Hematology Tags: Case Reports Source Type: research

Budget impact analysis of 8 hormonal contraceptive options.
Conclusions: Higher initial acquisition costs for the etonogestrel implant and levonorgestrel IUD were offset within 1 year by lower contraceptive failure rates and consequent pregnancy costs. Thus, after accounting for typical use failure rates of contraceptive products, the etonogestrel implant and levonorgestrel IUD emerged as the least expensive hormonal contraceptives. PMID: 23919444 [PubMed - in process] (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 10, 2013 Category: Health Management Authors: Crespi S, Kerrigan M, Sood V Tags: Am J Manag Care Source Type: research

Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring.
The objective of the present study was to investigate if temperature can be utilized to accelerate drug release from Nuvaring(®), a reservoir type intravaginal ring based on polyethylene vinyl acetate copolymer that releases a constant dose of contraceptive steroids over a duration of three weeks. The reciprocating holder apparatus (USP 7) was utilized to determine real-time and accelerated etonogestrel release from ring segments. It was demonstrated that drug release increased with increasing temperature which can be attributed to enhanced drug diffusion. An Arrhenius relationship of the zero-order release constants w...
Source: European Journal of Pharmaceutics and Biopharmaceutics - June 18, 2013 Category: Drugs & Pharmacology Authors: Externbrink A, Clark MR, Friend DR, Klein S Tags: Eur J Pharm Biopharm Source Type: research